Legal & General Group Plc Sells 3,871 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Legal & General Group Plc lowered its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 3.6% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 103,741 shares of the company’s stock after selling 3,871 shares during the period. Legal & General Group Plc owned approximately 0.22% of Amphastar Pharmaceuticals worth $3,852,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. Smartleaf Asset Management LLC lifted its position in shares of Amphastar Pharmaceuticals by 222.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock worth $26,000 after acquiring an additional 493 shares during the period. Parkside Financial Bank & Trust lifted its position in Amphastar Pharmaceuticals by 806.5% in the fourth quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock worth $36,000 after purchasing an additional 871 shares during the period. Huntington National Bank boosted its stake in Amphastar Pharmaceuticals by 36.9% during the fourth quarter. Huntington National Bank now owns 1,340 shares of the company’s stock worth $50,000 after buying an additional 361 shares in the last quarter. TD Private Client Wealth LLC increased its holdings in Amphastar Pharmaceuticals by 22.7% in the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company’s stock valued at $78,000 after buying an additional 388 shares during the period. Finally, KBC Group NV raised its stake in shares of Amphastar Pharmaceuticals by 43.1% in the 4th quarter. KBC Group NV now owns 2,159 shares of the company’s stock valued at $80,000 after buying an additional 650 shares in the last quarter. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Trading Up 1.8 %

AMPH stock opened at $23.93 on Wednesday. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of 7.98, a P/E/G ratio of 2.19 and a beta of 0.79. The business has a fifty day moving average price of $27.46 and a 200 day moving average price of $36.97. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $22.64 and a fifty-two week high of $53.96.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on AMPH. Piper Sandler lowered their target price on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research note on Friday, March 21st. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th.

Insider Activity

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the sale, the chief financial officer now owns 97,363 shares in the company, valued at approximately $2,681,377.02. This trade represents a 4.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 27.10% of the stock is currently owned by corporate insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.